Meta AnalysisID 6810

益气活血类中成药治疗冠状动脉微血管疾病的疗效与安全性:系统评价与Meta分析

CRD42023465454

To investigate the efficacy and safety of Yiqihuoxue Chinese Patent Medicines and Western Medicine in the Treatment of Coronary Microvascular Disease

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id
6810
Evidence Id
15368
Core Evidence Id
15368
Source Meta Analysis Id
6794
Herb2 Meta Analysis Id
HBMA006794
Crd Id
CRD42023465454
Title
Efficacy and safety of Yiqihuoxue Chinese Patent Medicines in the Treatment of Coronary Microvascular Disease: A Systematic Review and Meta-Analysis
Review Question
To investigate the efficacy and safety of Yiqihuoxue Chinese Patent Medicines and Western Medicine in the Treatment of Coronary Microvascular Disease
Study Type Included
RCTs
Condition Being Studied
The treatment of coronary microvascular disease is a difficult and hot topic in the field of cardiovascular disease at present. At present, modern medical intervention means are limited. More and more clinical studies show that the Yiqihuoxue traditional Chinese patent medicines have the potential clinical efficacy of improving CMD, but there is no relevant clinical evidence published based on systematic evaluation, Therefore, in the clinical part of this study, it is planned to explore the efficacy and safety of Yiqihuoxue traditional Chinese patent medicines in the intervention of CMD through Meta analysis and GRADE evidence evaluation, so as to clarify the current clinical evidence of this kind of traditional Chinese patent medicines in the intervention of CMD
Participant
The participants all need to undergo a microcirculation function evaluation (index of microcirculatory resistance(IMR)>25 or coronary flow reserve (CFR)<2 or TIMI frame method>25) to be diagnosed with CMD.
Animal
Human Disease Modelled
Intervention
On the basis of the control group, the intervention group was given any kind of oral Yiqihuoxue traditional Chinese patent medicines, including Tongxinluo Capsule, Qishen Yiqi Dropping Pill, Shexiang Baoxin Pill, etc.
Comparator Control
The control group received routine treatment drugs (including antiplatelet aggregation drugs, anticoagulants β- Receptor blockers, calcium antagonists, aldosterone receptor antagonists, statins, nicorandil, etc.), all of which must be applied within a reasonable dosage range.
Main Outcome
Microcirculatory function indicators (IMR, CFR) Measures of effect The analysis results of IMR and CFR are represented by mean difference.
Outcome Measure
Additional Outcome
① Clinical total effective rate; ② Electrocardiogram efficacy; ③ Inflammatory markers (hs-CRP); ④ Endothelial function indicators (NO). Measures of effect The analysis results of hs-CRP and NO are represented by mean difference, while the binary variables clinical total effective rate and clinical total effective rate are represented by risk ratios.
Study Method
Meta-analysis, Systematic review
Keyword
MeSH headings have not been applied to this record
Contact
Chen Jiaping [email protected]
Organisational Affiliation
capital medical university
Funding Source
This work was funded by National Natural Science Foundation of China(No. 8210151350).
Other Selection Criteria
Final Publication
Same Topic Review
Published Protocol
Review Type
Language
English
Country
China
Review Stage
Review Ongoing
First Submission Date
2023-09-20
Registration Date
2023-10-02
Anticipated Start Date
2023-09-01
Anticipated Completion Date
2023-12-31
Title Cn
益气活血类中成药治疗冠状动脉微血管疾病的疗效与安全性:系统评价与Meta分析
Title En
Efficacy and safety of Yiqihuoxue Chinese Patent Medicines in the Treatment of Coronary Microvascular Disease: A Systematic Review and Meta-Analysis
Bilingual Status
complete